Lyphe Clinic is thrilled to announce its partnership with Gro-Vida, a licensed medical cannabis cultivator.
This collaboration marks a significant step forward in advancing patient care and access to high-quality medical cannabis products within the UK.
By forming a strategic partnership with Gro-Vida, Lyphe Clinic aims to further enhance its commitment to providing superior care and uninterrupted access to medical cannabis treatments for its patients.
Sophie Gamwell, Managing Director at Lyphe Clinic, expressed her enthusiasm about the partnership, stating:
“We are delighted to join hands with Gro-Vida to ensure seamless access to medical cannabis for our patients. Guaranteeing a continuous and reliable supply of medication is paramount for their well-being, and this partnership enables us to fulfil that commitment.”
Gro-Vida, renowned for its dedication to producing high-quality medical cannabis products, is equally excited about the collaboration.
Mallory Bodnar, Managing Director at Gro-Vida, commented:
“Our partnership with Lyphe Clinic represents a significant step forward in our shared commitment to enhancing patient well-being. We are thrilled about this collaboration, which embodies our joint dedication to elevating standards of care. Together, we are ensuring that patients have access to high-quality, consistent medical cannabis.”
Through this partnership, Lyphe Clinic patients will benefit from a streamlined medical cannabis supply chain, ensuring consistent access to their prescribed medication. Additionally, the collaboration will empower Lyphe Clinic to exercise greater control over the quality and cost of the medical cannabis provided to its patients, ultimately enhancing the overall patient experience.
Gro-Vida is a privately held pharmaceutical company licenced for the cultivation of medical-grade cannabis flower addressed to international markets. Since 2019, Gro-Vida has been operational as one of the pioneering entities to receive licensing for the cultivation of medical cannabis in Portugal. The company owns and operates a 20,000m2 hybridised greenhouse allowing for year-round cultivation to meet the growing demand in the global cannabis market. With a comprehensive genetic repository spanning from CBD-dominant to High-THC cultivars, Gro-Vida has played a pivotal role in shaping the burgeoning medical market by offering a diverse array of cannabinoid-based medicines to customers worldwide.
Gro-Vida is a leader in the cultivation, production and manufacturing of phytocannabinoid therapeutics, supplying pharmaceutical partners throughout the United Kingdom, European Union and Australia. Gro-Vida provides GACP and EU-GMP-certified products to the global market, ensuring the highest standards of quality, safety, and efficacy to its partners.
To learn more about Gro-Vida and its products, visit www.gro-vida.com.
Lyphe is your patient-first path to wellness, so book an appointment with one of our medical cannabis expert Doctors and get the relief you need.
The content provided on this blog is intended for educational purposes only and should not be construed as medical advice. We strongly advise readers to seek guidance from a qualified healthcare professional regarding any medical concerns.
To reflect its medicinal nature rather than recreational use, we prefer the term ‘medical cannabis’ over terms such as ‘marijuana’, “grass”. or ‘dope’ which may carry negative connotations.
The opinions expressed in the blog belong to the respective authors, who are not medical professionals, and may not necessarily align with those of Lyphe Clinic. Lyphe Clinic does not endorse any specific products or services mentioned, except those provided through Lyphe Clinic.
Readers should be aware that the legality of medical cannabis varies by location, and this disclaimer may be subject to periodic updates.
Whilst you’re here you might also like to read…